On November 28th, BeiGene announced that its independently developed anti-PD-1 antibody Baize'an (Trastuzumab Injection) and BTK inhibitor Baiyueze (Zebutinib Capsules) have been added to the new version of the national medical insurance drug list with three new indications and one additional indication, respectively; The cooperative introduction of product Baituowei (injectable goserelin microspheres) has added an indication and been included in the national medical insurance drug catalog. Kailuos (injectable carfilzomide) has successfully renewed its contract.